Targeting B-cell germlines and focusing affinity maturation: The next hurdles in HIV-1-vaccine development?

Expert Review of Vaccines

Volumn 13, Issue 4, 2014, Pages 449-452

  Medina Ramírez, Max ^a   Sanders, Rogier W ^a,b   Klasse, Per Johan ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Vaccine

Indexed keywords

ENVELOPE PROTEIN; EPITOPE; GLYCOPEPTIDE; GLYCOPEPTIDE V1V2; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN BINDING; B LYMPHOCYTE; CELL MATURATION; COMPLEMENTARITY DETERMINING REGION; DRUG DESIGN; DRUG TARGETING; GERM LINE; GERMINAL CENTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGLOBULIN GENE; MITOTIC RECOMBINATION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTECTION; REVIEW; SIMULATION; SOMATIC HYPERMUTATION; VDJ RECOMBINATION; VIRUS STRAIN;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84896453729     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.894469     Document Type: Review

References (24)

1. Julien JP, Cupo A, Sok D, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013;342:1477-83
2. Lyumkis D, Julien JP, de Val N, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013;342:1484-90
3. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012;30:423-33
4. Klein F, Mouquet H, Dosenovic P, et al. Antibodies in HIV-1 vaccine development and therapy. Science 2013;341:1199-204
5. Sanders RW, Derking R, Cupo A, et al. A next-generation cleaved, soluble HIV-1 envelope Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 2013;9:e1003618
6. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011;477:466-70
7. Ringe RP, Sanders RW, Yasmeen A, et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci USA 2013;110:18256-61
8. Zhou T, Zhu J, Wu X, et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 2013;39:245-58
9. Hoot S, McGuire AT, Cohen KW, et al. Recombinant HIV envelope proteins fail to engage germline versions of anti- CD4bs bNAbs. PLoS Pathog 2013;9: e1003106
10. Jardine J, Julien JP, Menis S, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013;340: 711-16
11. Ota T, Doyle-Cooper C, Cooper AB, et al. Cell lines as candidate vaccine biosensors. J Immunol 2012;189:4816-24
12. Scharf L, West AP Jr, Gao H, et al. Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. Proc Natl Acad Sci USA 2013;110:6049-54
13. West AP Jr, Diskin R, Nussenzweig MC, Bjorkman PJ. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci USA 2012;109:E2083-90
14. McGuire AT, Hoot S, Dreyer AM, et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 2013;210:655-63
15. McGuire AT, Glenn JA, Lippy A, Stamatatos L. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J Virol 2013;88(5):2645-57
16. Mouquet H, Scheid JF, Zoller MJ, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010;467:591-5
17. Liao HX, Lynch R, Zhou T, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013;496:469-76
18. Alam SM, Dennison SM, Aussedat B, et al. Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proc Natl Acad Sci USA 2013;110:18214-19
19. Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol 2012;30: 429-57
20. Klein F, Diskin R, Scheid JF, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013;153:126-38
21. Georgiev IS, Rudicell RS, Saunders KO, et al. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J Immunol 2014;192:1100-6
22. Malherbe DC, Doria-Rose NA, Misher L, et al. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J Virol 2011;85: 5262-74
23. Wibmer CK, Bhiman JN, Gray ES, et al. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog 2013;9:e1003738
24. Bartesaghi A, Merk A, Borgnia MJ, et al. Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat Struct Mol Biol 2013;20:1352-7